Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A New Intervention for Implementation of Pharmacogenetics in Psychiatry

Project description

Tracing the capabilities of pharmacogenetics in psychiatric treatment

Despite the continuous development of treatments for patients with mental illness, crucial factors such as genetic heterogeneity, low compliance and commonly encountered side effects limit treatment efficacy. In contrast with the widespread practice of selecting medication through trial and error, pharmacogenetic testing enables the evaluation of person-specific factors that make the clinical response and side effects foreseeable. The EU-funded PSY-PGx project is introducing a large-scale non-industry sponsored clinical study in 6 European (related) countries and the US that demonstrates the clinical benefits and the potential of implementing pharmacogenetics for psychiatric patients in existing medical settings.

Objective

Due to the chronic relapsing nature of mental disorders and increased life expectancy, the societal burden of these non-communicable diseases will increase even further. Treatments for mental disorders are available, but their effect is limited due to patients’ (genetic) heterogeneity, low treatment compliance and frequent side effects. Only one-third of the patients respond to treatment. Today, medication selection in psychiatry relies on a trial-and-error approach based mainly on physicians’ experience. Pharmacogenetic testing enables assessing person-specific genetic factors that predict clinical response and side effects. Recent studies show that genotyping of drug-metabolizing enzymes can increase the effectiveness of treatment, which could benefit millions of patients. PSY-PGx is the first initiative to propose a large-scale non-industry sponsored clinical study that demonstrates the clinical benefits and potential of implementing pharmacogenetics for psychiatric patients in existing medical settings. To this end 1) available biobank data (www.biobankki.fi www.ukbiobank.ac.uk) with the aid of AI, will be searched for pharmacogenetics that influence medication response. This information is used to 2) perform a clinical trial that will be the first large international, multicenter clinical trial on using pharmacogenetic-based treatment personalization in real-life psychiatric care for depressed, anxiety or psychotic disorder patients. All data is combined with AI to set-up an algorithm for personalizing medication prescription for psychiatric patients that reduces side effects and increases effectiveness of pharmacotherapy. PSY-PGx will thus deliver a new model of care for sustainable healthcare systems and reduce the suffering of psychiatric patients.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

RIA - Research and Innovation action

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-SC1-BHC-2018-2020

See all projects funded under this call

Coordinator

PG ZORGHOLDING BV
Net EU contribution
€ 1 292 014,94
Address
MONSTERSEWEG 93
2553 RJ Den Haag
Netherlands
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 1 292 014,94

Participants (17)